Relationship of resistin levels with endometrial cancer risk

Neoplasma

Volumn 58, Issue 2, 2011, Pages 124-128

  Hlavna, M ^a   Kohut, L ^a   Lipkova, J ^a   Bienertova Vasku, J ^a   Dostalova, Z ^b   Chovanec, J ^b   Vasku, A ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Endometrial cancer; Resistin; SNP 420c>G

Indexed keywords

RESISTIN; RETN PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FEMALE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; AGED; BLOOD; ENDOMETRIUM TUMOR; GENETICS; GENOTYPE; INFANT; MIDDLE AGED;

ADULT; AGED; BODY MASS INDEX; ENDOMETRIAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; INFANT; MIDDLE AGED; RESISTIN;

EID: 79961122795     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_02_124     Document Type: Article

References (39)

1. DUSEK L, MUZIK J, KUBASEK M, KOPTIKOVA J, ZALOUDIK J, et al. Epidemiology of Malignant Tumours in the Czech Republic [online]. Masaryk University, Czech Republic, 2005, [cit. 2010-9-21]. http://www.svod.cz. Version 7.0, 2007, ISSN 1802-8861
2. TRAYHURN P, WOOD IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347-55. doi:10.1079/BJN20041213
3. KURMAN RJ, MCCONNELL TG. Precursors of endometrial and ovarian carcinoma. Virchows Arch; 456: 1-12. doi:10.1007/s00428-009-0824-9
4. BASTARD JP, MAACHI M, LAGATHU C, KIM J, CARON M, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4-12.
5. STEPPAN CM, BAILEY ST, BHAT S, BROWN J, BANERJEE R, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-12. doi:10.1038/35053000
6. RAJALA MW, OBICI S, SCHERER PE, ROSSETTI L. Adiposederived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003; 111: 225-30.
7. BECKERS S, PEETERS AV, FREITAS F, MERTENS L, HENDRICKX J, et al. Analysis of genetic variations in the resistin gene shows no associations with obesity in women. Obesity (Silver Spring) 2008; 16: 905-7. doi:10.1038/ oby.2007.131
8. BIK W, OSTROWSKI J, BARANOWSKABIK A, WOLIN-SKA-WITORT E, BIALKOWSKA M, et al. Adipokines and genetic factors in overweight or obese but metabolically healthy Polish women. Neuro Endocrinol Lett;31.
9. GHARIBEH MY, AL TAWALLBEH GM, ABBOUD MM, RADAIDEH A, ALHADER AA, et al. Correlation of plasma resistin with obesity and insulin resistance in type 2 diabetic patients. Diabetes Metab.
10. ZOU CC, LIANG L, HONG F. Relationship between insulin resistance and serum levels of adiponectin and resistin with childhood obesity. Indian Pediatr 2007; 44: 275-9.
11. STEPPAN CM, BROWN EJ, WRIGHT CM, BHAT S, BANER-JEE R, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci U S A 2001; 98: 502-6. doi:10.1073/ pnas.98.2.502
12. FRANKEL DS, VASAN RS, D'AGOSTINO RB, SR., BEN-JAMIN EJ, LEVY D, et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009; 53: 754-62. doi:10.1016/j.jacc.2008.07.073
13. BUTLER J, KALOGEROPOULOS A, GEORGIOPOULOU V, DE REKENEIRE N, RODONDI N, et al. Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study. Arterioscler Thromb Vasc Biol 2009; 29: 1144-9. doi:10.1161/ATVBAHA.109.186783
14. PISCHON T, BAMBERGER CM, KRATZSCH J, ZYRIAX BC, ALGENSTAEDT P, et al. Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005; 13: 1764-71. doi:10.1038/oby.2005.215
15. CHEN C, JIANG J, LU JM, CHAI H, WANG X, et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol; 299: H193-201. doi:10.1152/ajpheart.00431.2009
16. NAKAJIMA TE, YAMADA Y, HAMANO T, FURUTA K, GOTODA T, et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 2009; 44: 685-90. doi:10.1007/s00535-009-0063-5
17. AL-HARITHY RN, AL-GHAFARI AB. Resistin in human colon cancer. Increased expression independently of resistin promoter C-180G genotype. Saudi Med J; 31: 495-500.
18. HOU WK, XU YX, YU T, ZHANG L, ZHANG WW, et al. Adipocytokines and breast cancer risk. Chin Med J (Engl) 2007; 120: 1592-6.
19. KANG JH, YU BY, YOUN DS. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci 2007; 22: 117-21. doi:10.3346/jkms.2007.22.1.117
20. YILMAZ M, BUKAN N, DEMIRCI H, OZTURK C, KAN E, et al. Serum resistin and adiponectin levels in women with polycystic ovary syndrome. Gynecol Endocrinol 2009; 25: 246-52. doi:10.1080/09513590802653833
21. AZUMA K, KATSUKAWA F, OGUCHI S, MURATA M, YAMAZAKI H, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003; 11: 997-1001. doi:10.1038/oby.2003.137
22. SINORITA H, ASDIE RH, PRAMONO RB, PURNAMA LB, ASDIE AH. Leptin, Adiponectin and Resistin Concentration in Obesity Class I and II at Sardjito Hospital Yogyakarta. Acta Med Indones; 42: 74-7.
23. BAJNOK L, SERES I, VARGA Z, JEGES S, PETI A, et al. Relationship of serum resistin level to traits of metabolic syndrome and serum paraoxonase 1 activity in a population with a broad range of body mass index. Exp Clin Endocrinol Diabetes 2008; 116: 592-9. doi:10.1055/s-2008-1065350
24. OSAWA H, YAMADA K, ONUMA H, MURAKAMI A, OCHI M, et al. The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet 2004; 75: 678-86. doi:10.1086/424761
25. TSUKAHARA T, NAKASHIMA E, WATARAI A, HAMADA Y, NARUSE K, et al. Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 2009; 84: 179-86. doi:10.1016/ j.diabres.2008.10.021
26. HUSSAIN S, ASGHAR M, JAVED Q. Resistin gene promoter region polymorphism and the risk of hypertrophic cardiomyopathy in patients. Transl Res; 155: 142-7. doi:10.1016/j.trsl.2009.10.002
27. ONUM H, TABARA Y, KAWAMURA R, TANAKA T, OHASHI J, et al. A at single nucleotide polymorphism-358 is required for G at -420 to confer the highest plasma resistin in the general Japanese population. PLoS One;5:e9718. doi:10.1371/journal.pone.0009718
28. PATEL L, BUCKELS AC, KINGHORN IJ, MURDOCK PR, HOLBROOK JD, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472-6. doi:10.1016/S0006-291X(02)02841-3
29. BOKAREWA M, NAGAEV I, DAHLBERG L, SMITH U, TARKOWSKI A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789-95.
30. FANTUZZI G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-9; quiz 920. doi:10.1016/j.jaci.2005.02.023
31. SHETTY GK, ECONOMIDES PA, HORTON ES, MANT-ZOROS CS, VEVES A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-7. doi:10.2337/ diacare.27.10.2450
32. REILLY MP, LEHRKE M, WOLFE ML, ROHATGI A, LAZAR MA, et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-9. doi:10.1161/01. CIR.0000155620.10387.43
33. SINGH RK, LOKESHWAR BL. Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer 2009; 8: 57. doi:10.1186/1476-4598-8-57
34. FUJIMOTO J, AOKI I, KHATUN S, TOYOKI H, TAMAYA T. Clinical implications of expression of interleukin-8 related to myometrial invasion with angiogenesis in uterine endometrial cancers. Ann Oncol 2002; 13: 430-4. doi:10.1093/annonc/ mdf078
35. SEO KH, LEE HS, JUNG B, KO HM, CHOI JH, et al. Estrogen enhances angiogenesis through a pathway involving platelet activating factor-mediated nuclear factor-kappaB activation. Cancer Res 2004; 64: 6482-8. doi:10.1158/0008-5472.CAN03-2774
36. SUN CA, WU MH, CHU CH, CHOU YC, HSU GC, et al. Adipocytokine resistin and breast cancer risk. Breast Cancer Res Treat; 123: 869-76. doi:10.1007/s10549-010-0792-4
37. HARRIS RE, CHLEBOWSKI RT, JACKSON RD, FRID DJ, ASCENSEO JL, et al. Breast cancer and nonsteroidal antiinflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003; 63: 6096-101.
38. OUAKAA-KCHAOU A, ELLOUMI H, GARGOURI D, KHARRAT J, GHORBEL A. Helicobacter pylori and gastric cancer. Tunis Med; 88: 459-61.
39. WALLACE AE, GIBSON DA, SAUNDERS PT, JABBOUR HN. Inflammatory events in endometrial adenocarcinoma. J Endocrinol; 206: 141-57.